Tauroursodeoxycholic acid (TUDCA) is a bile acid derivative originally studied in the context of cholestatic liver diseases. There is scientific evidence supporting its use for specific liver conditions, particularly those involving impaired bile flow or hepatocellular injury. TUDCA is known to help reduce endoplasmic reticulum (ER) stress, protect hepatocytes from apoptosis, and improve bile acid homeostasis. These mechanisms have been observed in preclinical studies and some human clinical trials, primarily for primary biliary cholangitis, nonalcoholic fatty liver disease (NAFLD), and certain cholestatic disorders.

However, the term "liver detoxification" is vague and not a formally recognized medical diagnosis. While TUDCA has demonstrated hepatoprotective properties and can support liver function in the context of specific liver diseases, there is limited evidence directly supporting its use for generalized "detoxification" in healthy individuals. Most available data are from animal studies, cellular models, and small-scale clinical trials in patients with established liver pathology. Large, well-controlled human studies are lacking, especially in healthy populations seeking general detoxification.

In summary, TUDCA has a scientific basis for supporting liver health in certain disease contexts, but its use for "liver detoxification" in healthy people is not robustly validated. The overall evidence is moderate (3/5), with the strongest support in targeted liver diseases rather than broad detoxification claims.